798 related articles for article (PubMed ID: 32535894)
1. Bloodstream infections in critically ill patients with COVID-19.
Giacobbe DR; Battaglini D; Ball L; Brunetti I; Bruzzone B; Codda G; Crea F; De Maria A; Dentone C; Di Biagio A; Icardi G; Magnasco L; Marchese A; Mikulska M; Orsi A; Patroniti N; Robba C; Signori A; Taramasso L; Vena A; Pelosi P; Bassetti M
Eur J Clin Invest; 2020 Oct; 50(10):e13319. PubMed ID: 32535894
[TBL] [Abstract][Full Text] [Related]
2. Enterococcal bloodstream infections in critically ill patients with COVID-19: a case series.
Giacobbe DR; Labate L; Tutino S; Baldi F; Russo C; Robba C; Ball L; Dettori S; Marchese A; Dentone C; Magnasco L; Crea F; Willison E; Briano F; Battaglini D; Patroniti N; Brunetti I; Pelosi P; Bassetti M
Ann Med; 2021 Dec; 53(1):1779-1786. PubMed ID: 34637370
[TBL] [Abstract][Full Text] [Related]
3. Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial.
Busani S; Tosi M; Mighali P; Vandelli P; D'Amico R; Marietta M; Forfori F; Donati A; Cinnella G; De Monte A; Pasero D; Bellani G; Tascini C; Foti G; Ranieri M; Girardis M
Trials; 2020 Aug; 21(1):724. PubMed ID: 32807241
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of SARS-CoV-2 preventive measures against ESKAPE and Escherichia coli infections.
Gaspari R; Spinazzola G; Teofili L; Avolio AW; Fiori B; Maresca GM; Spanu T; Nicolotti N; De Pascale G; Antonelli M
Eur J Clin Invest; 2021 Dec; 51(12):e13687. PubMed ID: 34599600
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and Prognosis of Intensive Care Unit-Acquired Bloodstream Infection.
Kallel H; Houcke S; Resiere D; Roy M; Mayence C; Mathien C; Mootien J; Demar M; Hommel D; Djossou F
Am J Trop Med Hyg; 2020 Jul; 103(1):508-514. PubMed ID: 32314689
[TBL] [Abstract][Full Text] [Related]
7. Intensive-care-unit-acquired bloodstream infections in a regional critically ill population.
Laupland KB; Kirkpatrick AW; Church DL; Ross T; Gregson DB
J Hosp Infect; 2004 Oct; 58(2):137-45. PubMed ID: 15474185
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.
Jiménez-Brítez G; Ruiz P; Soler X
Med Clin (Barc); 2020 Nov; 155(9):410-411. PubMed ID: 32718713
[No Abstract] [Full Text] [Related]
9. Incidence, Risk Factors, and Prognosis of Bloodstream Infections in COVID-19 Patients in Intensive Care: A Single-Center Observational Study.
Kurt AF; Mete B; Urkmez S; Demirkiran O; Dumanli GY; Bozbay S; Dilken O; Karaali R; Balkan II; Saltoğlu N; Dikmen Y; Tabak F; Aygun G
J Intensive Care Med; 2022 Oct; 37(10):1353-1362. PubMed ID: 35607286
[TBL] [Abstract][Full Text] [Related]
10. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K
Int J Rheum Dis; 2020 Aug; 23(8):1030-1039. PubMed ID: 32881350
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal Perforation After Treatment With Tocilizumab : An Unexpected Consequence of COVID-19 Pandemic.
Rojo M; Cano-Valderrama O; Picazo S; Saez C; Gómez L; Sánchez C; Sanz-Ortega G; Torres AJ
Am Surg; 2020 Jun; 86(6):565-566. PubMed ID: 32683974
[No Abstract] [Full Text] [Related]
13. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.
Grasselli G; Greco M; Zanella A; Albano G; Antonelli M; Bellani G; Bonanomi E; Cabrini L; Carlesso E; Castelli G; Cattaneo S; Cereda D; Colombo S; Coluccello A; Crescini G; Forastieri Molinari A; Foti G; Fumagalli R; Iotti GA; Langer T; Latronico N; Lorini FL; Mojoli F; Natalini G; Pessina CM; Ranieri VM; Rech R; Scudeller L; Rosano A; Storti E; Thompson BT; Tirani M; Villani PG; Pesenti A; Cecconi M;
JAMA Intern Med; 2020 Oct; 180(10):1345-1355. PubMed ID: 32667669
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network.
Buetti N; Ruckly S; de Montmollin E; Reignier J; Terzi N; Cohen Y; Siami S; Dupuis C; Timsit JF
Intensive Care Med; 2021 Feb; 47(2):180-187. PubMed ID: 33506379
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.
Patel A; Shah K; Dharsandiya M; Patel K; Patel T; Patel M; Reljic T; Kumar A
Indian J Med Microbiol; 2020; 38(1):117-123. PubMed ID: 32719218
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.
Klopfenstein T; Zayet S; Lohse A; Balblanc JC; Badie J; Royer PY; Toko L; Mezher C; Kadiane-Oussou NJ; Bossert M; Bozgan AM; Charpentier A; Roux MF; Contreras R; Mazurier I; Dussert P; Gendrin V; Conrozier T;
Med Mal Infect; 2020 Aug; 50(5):397-400. PubMed ID: 32387320
[TBL] [Abstract][Full Text] [Related]
17. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab treatment in COVID-19: A single center experience.
Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
[TBL] [Abstract][Full Text] [Related]
19. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A;
JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385
[TBL] [Abstract][Full Text] [Related]
20. Superinfections in patients treated with Teicoplanin as anti-SARS-CoV-2 agent.
Ceccarelli G; Alessandri F; Oliva A; Dell'Isola S; Rocco M; Ruberto F; Pugliese F; d'Ettorre G; Venditti M
Eur J Clin Invest; 2021 Jan; 51(1):e13418. PubMed ID: 32997792
[No Abstract] [Full Text] [Related]
[Next] [New Search]
